Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

In the world of consumer marketing, people-based data has become the gold standard. Demographics are just the starting point. Layered on top are deep behavioural insights into what people buy, browse, ...

The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Zheng Su discusses the key challenges in clinical trials across the Western and emerging regions, specifically looking at patient recruitment and clinical research. The past decades have witnessed ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug in the ...